First Time Loading...

Gland Pharma Ltd
NSE:GLAND

Watchlist Manager
Gland Pharma Ltd Logo
Gland Pharma Ltd
NSE:GLAND
Watchlist
Price: 1 710 INR 1% Market Closed
Updated: May 11, 2024
Section:
 

Relative Value

The Relative Value of one GLAND stock under the Base Case scenario is 2 400.48 INR. Compared to the current market price of 1 710 INR, Gland Pharma Ltd is Undervalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLAND Relative Value
Base Case
2 400.48 INR
Undervaluation 29%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.7
P/S
P/S
Price to Sales
5.7
vs History
84
vs Industry
24
Median 3Y
7.3
Median 5Y
7.3
Industry
2.5
Forward
4.8
More Details
42.8
P/E
P/E
Price to Earnings
42.8
vs History
43
vs Industry
10
Median 3Y
42.2
Median 5Y
39.7
Industry
23.4
Forward
31.9
More Details
72.2
P/OCF
P/OCF
Price to OCF
72.2
vs History
40
vs Industry
5
Median 3Y
70.7
Median 5Y
66.6
Industry
17.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
1
Median 3Y
118.6
Median 5Y
110.6
Industry
24.1
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
75
vs Industry
23
Median 3Y
3.9
Median 5Y
4.9
Industry
2.1
More Details
5.3
EV/S
EV/S
Enterprise Value to Sales
5.3
vs History
79
vs Industry
24
Median 3Y
6.5
Median 5Y
6.7
Industry
2.6
Forward
4.5
More Details
8.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.8
vs History
84
vs Industry
25
Median 3Y
12.3
Median 5Y
12.2
Industry
5.2
More Details
24.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
24.3
vs History
59
vs Industry
15
Median 3Y
25.9
Median 5Y
25.4
Industry
13.9
Forward
18.7
More Details
30.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.7
vs History
52
vs Industry
14
Median 3Y
31
Median 5Y
30.6
Industry
17.5
Forward
23.9
More Details
67.1
EV/OCF
EV/OCF
Enterprise Value to OCF
67.1
vs History
40
vs Industry
6
Median 3Y
65.6
Median 5Y
62
Industry
16.4
More Details
314.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
314.4
vs History
13
vs Industry
2
Median 3Y
126
Median 5Y
123.6
Industry
18.1
More Details
3.6
EV/IC
EV/IC
Enterprise Value to IC
3.6
vs History
86
vs Industry
23
Median 3Y
5.7
Median 5Y
7.5
Industry
1.9
More Details

Multiples Across Competitors

GLAND Competitors Multiples
Gland Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Gland Pharma Ltd
NSE:GLAND
281.6B INR 5.7 42.8 24.3 30.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.7
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
IN
Gland Pharma Ltd
NSE:GLAND
Average P/E: 52.7
42.8
58%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
GLAND intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLAND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLAND stock valuation using valuation multiples.
Wall Street Estimates
GLAND price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLAND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.